Halozyme Therapeutics, Inc. $HALO Shares Acquired by Legal & General Group Plc

Legal & General Group Plc lifted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 7.5% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 337,567 shares of the biopharmaceutical company’s stock after buying an additional 23,475 shares during the quarter. Legal & General Group Plc owned 0.27% of Halozyme Therapeutics worth $17,560,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of HALO. Alliancebernstein L.P. raised its stake in shares of Halozyme Therapeutics by 4.8% during the first quarter. Alliancebernstein L.P. now owns 3,215,109 shares of the biopharmaceutical company’s stock valued at $205,156,000 after purchasing an additional 146,677 shares during the period. Dimensional Fund Advisors LP increased its stake in Halozyme Therapeutics by 4.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,029,160 shares of the biopharmaceutical company’s stock worth $129,478,000 after buying an additional 95,600 shares during the period. LSV Asset Management lifted its holdings in Halozyme Therapeutics by 40.2% in the 2nd quarter. LSV Asset Management now owns 1,255,240 shares of the biopharmaceutical company’s stock worth $65,298,000 after buying an additional 360,049 shares in the last quarter. Fuller & Thaler Asset Management Inc. boosted its position in Halozyme Therapeutics by 27.3% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,130,019 shares of the biopharmaceutical company’s stock valued at $72,107,000 after buying an additional 242,167 shares during the last quarter. Finally, Los Angeles Capital Management LLC grew its stake in shares of Halozyme Therapeutics by 951.8% during the second quarter. Los Angeles Capital Management LLC now owns 973,670 shares of the biopharmaceutical company’s stock valued at $50,650,000 after acquiring an additional 881,094 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Leerink Partnrs raised Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 14th. HC Wainwright reiterated a “buy” rating and set a $90.00 target price on shares of Halozyme Therapeutics in a research note on Friday. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Tuesday, November 4th. Morgan Stanley reduced their price objective on shares of Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating on the stock in a research note on Monday, October 20th. Finally, Wall Street Zen raised shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Sunday, November 16th. Seven research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $75.10.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock opened at $71.39 on Friday. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01. Halozyme Therapeutics, Inc. has a 12 month low of $46.26 and a 12 month high of $79.50. The company has a fifty day moving average price of $69.25 and a two-hundred day moving average price of $63.75. The company has a market cap of $8.39 billion, a PE ratio of 16.34, a P/E/G ratio of 0.35 and a beta of 1.18.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.63 by $0.09. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The company had revenue of $354.26 million for the quarter, compared to the consensus estimate of $339.18 million. During the same period last year, the firm posted $1.27 EPS. The company’s revenue for the quarter was up 22.1% on a year-over-year basis. Research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insider Buying and Selling at Halozyme Therapeutics

In other news, CFO Nicole Labrosse sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $75.71, for a total transaction of $1,514,200.00. Following the completion of the transaction, the chief financial officer directly owned 24,306 shares of the company’s stock, valued at approximately $1,840,207.26. This represents a 45.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bernadette Connaughton sold 4,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $73.68, for a total value of $294,720.00. Following the completion of the sale, the director directly owned 46,952 shares in the company, valued at approximately $3,459,423.36. This trade represents a 7.85% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 110,227 shares of company stock worth $8,028,955 over the last ninety days. Company insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.